

Report Information

More information from: <https://www.marketresearchfuture.com/reports/anti-asthma-drugs-market-2353>

Anti Asthma Drugs Market Research Report – Global Forecast to 2032

Report / Search Code: MRFR/Pharma/1736-HCR

Publish Date: February, 2024

[Request Sample](#)

Price	1-user PDF : \$ 4950.0	Site PDF : \$ 5950.0	Enterprise PDF : \$ 7250.0
-------	------------------------	----------------------	----------------------------

Description:

Anti Asthma Drugs Market Overview

The Anti Asthma Drugs Market is anticipated to reach USD 26.86 Billion by 2032 at 4.9% CAGR during the forecast period 2023-2032. The anti asthma drugs market size is expected to reach approximately, 300 Million people suffering from asthma during the historic forecast period and the figures are mounting which is blamed on increased pollution and unhealthy lifestyles. Asthma is a chronic lung illness marked by hyperresponsiveness of the tracheobronchial smooth muscle to stimuli, resulting in air tube restriction and inflammation, as well as increased secretion, edema, and fluid build-up. Tightness in the chest, wheezing, coughing, and possible limitations in activities due to breathing difficulties are some of the symptoms. The anti-asthmatics pharmaceuticals market includes sales of anti-asthmatics drugs by companies that make them. Manufacturers of anti-asthmatic medications such as bronchodilators, anti-inflammatory pharmaceuticals, monoclonal antibodies, and combination therapies make up the anti-asthmatics drug sector. Asthma is a disorder that causes the body's airways to restrict, swell, and produce excess mucus. Coughing, wheezing on exhale, and shortness of breath can occur as a result of this.

COVID Analysis

According to a study published in the European Respiratory Journal during the historic forecast period by José Luis Izquierdo, allergy-related variables such as rhinitis and eczema were less common in asthmatic patients with COVID-19. These comorbidities were found to be very common in COVID-19 individuals who needed to be admitted to the hospital. Furthermore, when compared to non-hospitalized patients, the use of inhaled corticosteroids (ICS) was lower in individuals who required hospitalization due to COVID-19. Even though patients treated with biologics had higher severity and more comorbidities in the ear, nose, and throat, COVID-19-related hospitalizations were quite low in these patients. As a result of comorbidity-related characteristics, patients with asthma and COVID-19 were older and at higher risk.

When COVID-19 strikes, patients with chronic obstructive pulmonary disease (COPD) are at a higher risk of severe pneumonia and poor outcomes. This could be due to a lack of underlying lung reserves or enhanced ACE-2 receptor expression in narrow airways. There is growing evidence that Asthma may be a risk factor for more severe COVID-19 disease. Even after adjusting for age and smoking, an examination of comorbidities in 1,590 COVID-19 patients across China found that Asthma had an odds ratio of 2.681 for ICU admission, mechanical ventilation, or death. Asthma was present in 62.5% of severe cases (compared to 15.3% in non-severe cases), and Asthma patients made up 25% of those who died (compared with only 2.8% of those who survived). Thus, the Anti Asthma Drugs Market Growth has increased during the pandemic times.

The tracheobronchial smooth muscle is hyperresponsive to stimuli in asthma, which causes airway obstruction and inflammation as well as enhanced secretion, edema, and fluid accumulation. Some symptoms include chest tightness, wheezing, coughing, and perhaps limitations on activities owing to breathing issues. Sales of anti-asthmatic medications by their manufacturers are included in the anti-asthmatic pharmaceuticals market. The anti-asthmatic drug industry consists of businesses producing anti-asthmatic drugs, including bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination treatments. The illness known as asthma makes the body's airways constrict, swell, and create too much mucus. This can lead to shortness of breath, wheezing on exhalation, and coughing.

The rise in the geriatric population is anticipated to aid in the market's expansion because this demographic is more susceptible to getting asthma conditions. To grow their market shares, the market participants use various techniques, including new launches, developments, partnerships, purchases, and expansions. As a result, it is anticipated that factors such as an upsurge in asthma and COPD prevalence, innovative therapy medications, and rising product developments will aid in the market's expansion. Furthermore, it is projected that technology developments would open profitable business chances for the industry. The biggest danger of allergies is that they cause asthma. Aside from irritants, exercise, blockages, cold air, animals, and dust, asthma can also be triggered by these factors.

Chronic obstructive pulmonary disease, or COPD, is characterized by airflow restriction and is not curable. COPD encompasses chronic bronchitis, an ongoing inflammation of the lower part of the lungs, and emphysema, a complex lung condition characterized by the loss of the alveoli. The use of tobacco is the main contributor to COPD. COPD risk factors include ambient air pollution, occupational exposure, and passive smoking. The late start of action and limited efficacy of conventional therapies are predicted to promote the creation of novel targeted medications, increasing the market.

Anti Asthma Drugs Market Dynamics

Drivers

Growing awareness of the benefits of modern drug therapy, a strong pipeline of anti-asthma drugs with some novel molecules, an increase in patients due to increased pollution, and the great potential of biologics, which is expected to

dominate the future market, are all factors that favor Anti-Asthma Drugs Market Growth during the Anti Asthma Drugs Market Analysis. The rising prevalence of respiratory disorders, increased incidence of cigarette smoking, global warming, aging population, growing markets, innovative technologies for drug discovery, and an increase in healthcare expenditure have all been growth factors in the past that have changed the Anti Asthma Drugs Market Outlook. It's encouraging to see that we believe the market's growth factors will outweigh the restraints and that the biologics segment's commercialization will propel the Anti Asthma Drugs Market Value forward and increase the Anti Asthma Drugs Market Trends.

Restraints

Loss of patents on top names like Advair and Symbicort, market fragmentation, and generic penetration are all limiting considerations. Side effects connected with respiratory medications, a decline in free trade, and stringent regulations are all factors that could slow the Anti Asthma Drugs Market Value and Anti Asthma Drugs Market Trends in the future. In the projected years, side effects associated with respiratory medicines are expected to impede market expansion. Asthma sufferers are subjected to a variety of respiratory medication adverse effects. Dry mouth, headaches, constipation, fast heartbeat, muscle cramps, and shaking are some of the most common side effects. Inhaled steroids used to treat asthma can cause thrush (a yeast infection in the mouth) and hoarseness in some people. As a result, doctors are increasingly offering alternative therapies to their patients, such as herbs and dietary supplements, yoga, relaxation, and acupuncture. In the forecast period, the Anti Asthma Drugs Market Size is likely to be limited by an increasing preference for alternative therapies for the treatment of asthma during the Anti Asthma Drugs Market Analysis.

Participants in the Global Anti Asthma Drugs Market will benefit from technological advancements and improvements in the coming years. Asthma is getting more common among the world's population even during the COVID era. The installed base of various types of products for the Anti Asthma Drugs Market Analysis has grown as a result of technological developments. An increase in the incidence and prevalence of asthma, technological improvements, and the expanding elderly population are some of the reasons driving the market growth. Furthermore, technological advances are expected to generate profitable prospects for the industry. Traditional therapy limitations, such as late-onset of action and low efficacy, are expected to drive the development of novel targeted drugs, enhancing future Anti-Asthma Drugs Market Outlook.

Anti Asthma Drugs Market Segment Overview

The Global Anti Asthma Drugs Market is further bifurcated into various segments depending on various factors to help the market to grow as per the predicted CAGR growth by the end of the forecast period in 2027. The Global Anti Asthma Drugs Market is segmented based on the following:

Based on the drug class, the market is segmented on the following:

- Bronchodilators
- Monoclonal Antibodies
- Anti-inflammatory Drugs
- Combination Drugs

Based on the end-user, the market is segmented on the following:

- Asthma Patients
- COPD Patients

Based on the distribution channel, the market is segmented on the following:

- General Pharmacies
- Hospital Pharmacies
- Online Retailers
- Others

Based on the therapy, the market is segmented on the following:

- Preventive
- Curative

Based on the route of administration, the market is segmented on the following:

- Oral
- Inhaled
- Intravenous
- Subcutaneous

News:

In a deal that might bring Jiangsu Hengrui Pharmaceutical up to USD 1 billion, the Chinese pharmaceutical company is giving US drugmaker One Bio the sole license to develop and market its brand-new asthma therapy in all markets outside China. Except for China, One Bio will have the exclusive right to manufacture, market, and distribute SHR-

1905, a monoclonal antibody injection used to treat severe asthma. One Bio, situated in Florida, must pay an upfront sum of \$21.5 million and receive an initial milestone payment of \$3.5 million in return, it was noted. If the new medication receives US, Japanese, and specific European country approvals, all development, and sales payments for milestones will not exceed USD 1 billion. After releasing the drug, One Bio will also provide Hengrui Pharma with a double-digit sales commission.

Anti Asthma Drugs Market Regional Classification

North America is the world's largest market for anti-asthma drugs. Anti-asthma drugs market has the second-largest market in Europe. The rising frequency of disorders like asthma, the aging population, increased research and development activities, and the existence of important market participants are all contributing to this growth. Because of better screening and distribution of health care facilities, the developing world, particularly the Asia Pacific, is accounting for a large number of novel cases. However, the market in developing regions, particularly the Asia Pacific, will rise at the fastest rate and will be the most important in the future.

Anti Asthma Drugs Market Competitive Landscape

Leading competitors in the Anti Asthma Drug markets are focusing on expanding their operations in emerging markets. The market's players have continually launched novel solutions to expand their product offerings. The two most common growth tactics used by significant market players are product approval and clinical trials. The major key players operating in the global anti-asthma drugs market are

- GlaxoSmithKline plc.
- Merck & Co., Inc.
- AstraZeneca plc.
- Hoffmann-La Roche Ltd
- Teva Pharmaceutical Industries
- Innoviva, Inc.
- Novartis International AG
- Boehringer Ingelheim
- Chiesi Farmaceutici S.p.A.
- Sunovion Pharmaceuticals Inc.
- Others

Recent Developments

- Chiesi Farmaceutici S.p.A. has begun a phase III clinical research (PILASTER study) to assess the efficacy and safety of two doses of CHF6001 (Tanimilast) as an add-on to maintenance triple treatment in patients with Asthma.
- Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') from GlaxoSmithKline Plc and Innoviva, Inc. has been approved by the US Food and Drug Administration (FDA) for the treatment of asthma in patients aged 18 and above.

Report Overview

Growth is one of a series of new reports that provides market overviews, analyses, and forecasts market size and growth for the entire market, segments and regions, drivers, restraints, key competitors' revenues, profiles, market shares, and market segments. The influence of COVID-19 on the market is also examined in depth in the research. Based on industry trends and leading rivals' methods, the studies indicate top countries and segments for opportunities and strategies. According to the report, Competitive intelligence identifies the strategies used by prominent market competitors in distinct geographic locations. In this study, key market players in the asthma medicine industry are profiled, and their tactics are thoroughly examined, predicting the competitive picture of the worldwide asthma drug market.

Table of Content:

Contents
Table of Contents
1 Introduction
1.1 Definition
1.2 Scope of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter's five forces model
4.1.1 Bargaining Power of suppliers

- 4.1.2 Bargaining Power of Customer
- 4.1.3 Intensity of Competitor's
- 4.1.4 Threat of New Entrants
- 5 Global anti-asthma drugs market, by type**
- 5.1 Introduction
- 5.1.1 Allergic (extrinsic)
- 5.1.2 Non-allergic (intrinsic) asthma
- 6 Global anti-asthma drugs market, by trigger**
- 6.1 Introduction
- 6.1.1 Child-onset asthma
- 6.1.2 Adult-onset asthma
- 6.1.3 Exercise-induced asthma
- 6.1.4 Cough-induced asthma
- 6.1.5 Occupational asthma
- 6.1.6 Nocturnal asthma
- 6.1.7 Steroid-resistant asthma
- 7 Global anti-asthma drugs market, by drug class**
- 7.1 Introduction
- 7.1.1 Bronchodilators (beta agonists, anti-cholinergics, xanthines)
- 7.1.2 Leukotriene antagonists
- 7.1.3 Mast cell stabilizers
- 7.1.4 Corticosteroids
- 7.1.5 Monoclonal antibody
- 7.1.6 Others
- 8 Global anti-asthma drugs market, by therapy**
- 8.1 Introduction
- 8.1.1 Preventive
- 8.1.2 Curative
- 9 Global anti-asthma drugs market, by route of administration**
- 9.1 Introduction
- 9.1.1 Oral
- 9.1.2 Inhaled
- 9.1.3 Intravenous
- 9.1.4 Subcutaneous
- 10 Global anti-asthma drugs market, by Regions**
- 10.1 Introduction
- 10.1.1 Americas
- 10.1.1.1 North America
- 10.1.1.2 South America
- 10.1.2 Europe
- 10.1.2.1 Germany
- 10.1.2.2 France
- 10.1.2.3 UK
- 10.1.2.4 Italy
- 10.1.2.5 Spain
- 10.1.2.6 Rest of Europe
- 10.1.3 Asia Pacific
- 10.1.3.1 Japan
- 10.1.3.2 China
- 10.1.3.3 India
- 10.1.3.4 Republic of Korea
- 10.1.3.5 Rest of Asia Pacific
- 10.1.4 Middle East & Africa
- 11 Company Landscape**
- 11.1 Introduction
- 11.1.1 Mergers Acquisitions
- 11.1.2 Collaborations
- 11.1.3 Release/New Product Launch
- 11.1.4 Other (Expansion, Updates, Partnership)
- 12 Company Profile**
- 12.1 GlaxoSmithKline plc.
- 12.1.1 Company Overview
- 12.1.2 Product/Business Segment Overview
- 12.1.3 Financials
- 12.1.4 Key Developments
- 12.1.5 SWOT Analysis
- 12.2 Merck & Co., Inc.
- 12.2.1 Overview
- 12.2.2 Product/Business Segment Overview
- 12.2.3 Financials
- 12.2.4 Key Developments
- 12.2.5 SWOT Analysis
- 12.3 AstraZeneca plc.
- 12.3.1 Overview
- 12.3.2 Product/Business Segment Overview
- 12.3.3 Financials
- 12.3.4 Key Developments
- 12.3.5 SWOT Analysis
- 12.4 F. Hoffmann-La Roche Ltd
- 12.4.1 Overview
- 12.4.2 Product/Business Segment Overview
- 12.4.3 Financials
- 12.4.4 Key Developments
- 12.4.5 SWOT Analysis
- 12.5 Teva Pharmaceutical Industries
- 12.5.1 Overview
- 12.5.2 Product/Business Segment Overview
- 12.5.3 Financials
- 12.5.4 Key Developments
- 12.5.5 SWOT Analysis
- 12.6 Novartis International AG
- 12.6.1 Overview
- 12.6.2 Product/Business Segment Overview

- 12.6.3 Financials
- 12.6.4 Key Developments
- 12.6.5 SWOT Analysis
- 12.7 Boehringer Ingelheim
 - 12.7.1 Overview
 - 12.7.2 Product/Business Segment Overview
 - 12.7.3 Financials
 - 12.7.4 Key Developments
 - 12.7.5 SWOT Analysis
- 12.8 Sunovion Pharmaceuticals Inc.
 - 12.8.1 Overview
 - 12.8.2 Product/Business Segment Overview
 - 12.8.3 Financials
 - 12.8.4 Key Developments
 - 12.8.5 SWOT Analysis
- 13 Others**
- 14 Appendix**
 - List of Tables
 - TABLE 1 GLOBAL ANTI-ASTHMA DRUGS MARKET, 2020-2027 (USD MILLION)
 - TABLE 2 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY TYPES, 2020-2027 (USD MILLION)
 - TABLE 3 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY TRIGGER, 2020-2027 (USD MILLION)
 - TABLE 4 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
 - TABLE 5 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY THERAPY, 2020-2027 (USD MILLION)
 - TABLE 6 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
 - TABLE 7 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)